Dataset Information

Low-dose hydrocortisone reduces norepinephrine duration in severe burn patients: a randomized clinical trial.

ABSTRACT: The aim of this study was to assess the effect of low-dose corticosteroid therapy in reducing shock duration after severe burn.A placebo-controlled, double-blind, randomized clinical trial (RCT) was performed on two parallel groups in the burn intensive care unit (ICU). Patients were randomized to receive either low-dose corticosteroid therapy or placebo for seven days. A corticotropin test was performed at the time of randomization, before the administration of the treatment dose. Thirty-two severely burned patients with refractory shock (>0.5 ?g/kg/min of norepinephrine) were prospectively included in the study.We included 12 patients in the hydrocortisone-treated group and 15 patients in the placebo group in the final analysis. Among these patients, 21 were nonresponders to the corticotropin test. Median norepinephrine treatment duration (primary objective) was significantly lower in the corticosteroid-treated versus the placebo group (57 hours versus 120 hours, P?=?0.035). The number of patients without norepinephrine 72 hours after inclusion was significantly lower in the treated group (P?=?0.003, log-rank test analysis). The total quantities of norepinephrine administered to patients were lower in the hydrocortisone-treated versus the placebo group (1,205 ?g/kg (1,079 to 2,167) versus 1,971 ?g/kg (1,535 to 3,893), P?=?0.067). There was no difference in terms of ICU or hospital length of stay, sepsis incidence, cicatrization or mortality.In this placebo-controlled, randomized, double-blind clinical trial, we show for the first time that the administration of low-dose hydrocortisone in burn patients with severe shock reduces vasopressor administration.Clinicaltrial.gov NCT00149123 . Registered 6 September 2005.

SUBMITTER: Venet F

PROVIDER: S-EPMC4347659 | biostudies-literature | 2015 Jan

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Low-dose hydrocortisone reduces norepinephrine duration in severe burn patients: a randomized clinical trial.

Venet Fabienne F Plassais Jonathan J Textoris Julien J Cazalis Marie-Angélique MA Pachot Alexandre A Bertin-Maghit Marc M Magnin Christophe C Rimmelé Thomas T Monneret Guillaume G Tissot Sylvie S

Critical care (London, England) 20150126

<h4>Introduction</h4>The aim of this study was to assess the effect of low-dose corticosteroid therapy in reducing shock duration after severe burn.<h4>Methods</h4>A placebo-controlled, double-blind, randomized clinical trial (RCT) was performed on two parallel groups in the burn intensive care unit (ICU). Patients were randomized to receive either low-dose corticosteroid therapy or placebo for seven days. A corticotropin test was performed at the time of randomization, before the administration ...[more]

PMID: 25619170

Similar Datasets

Project description:Estrogen therapy is the gold standard treatment for hot flashes and night sweats, but some women are unable or unwilling to use it because of associated risks. The serotonin-norepinephrine reuptake inhibitor venlafaxine hydrochloride is used widely as a nonhormonal treatment. While the clinical impression is that serotonin-norepinephrine reuptake inhibitors are less effective than estrogen, these medications have not been simultaneously evaluated in one clinical trial to date.To determine the efficacy and tolerability of low-dose oral 17?-estradiol and low-dose venlafaxine extended release in alleviating vasomotor symptoms (VMS).In total, 339 perimenopausal and postmenopausal women with at least 2 bothersome VMS per day (mean, 8.1 per day) were recruited from the community to MsFLASH (Menopause Strategies: Finding Lasting Answers for Symptoms and Health) clinical network sites between December 5, 2011, and October 15, 2012.Participants were randomized to double-blind treatment with low-dose oral 17?-estradiol (0.5 mg/d) (n?=?97), low-dose venlafaxine hydrochloride extended release (75 mg/d) (n?=?96), or placebo (n?=?146) for 8 weeks.The primary outcome was the mean daily frequency of VMS after 8 weeks of treatment. Secondary outcomes were VMS severity, bother, and interference with daily life. Intent-to-treat analyses compared the change in VMS frequency between each active intervention and placebo and between the 2 active treatments.Compared with baseline, the mean VMS frequency at week 8 decreased to 3.9 (95% CI, 2.9-4.9) VMS per day (52.9% reduction) in the estradiol group, to 4.4 (95% CI, 3.5-5.3) VMS per day (47.6% reduction) in the venlafaxine group, and to 5.5 (95% CI, 4.7-6.3) VMS per day (28.6% reduction) in the placebo group. Estradiol reduced the frequency of symptoms by 2.3 more per day than placebo (P?<?.001), and venlafaxine reduced the frequency of symptoms by 1.8 more per day than placebo (P?=?.005). The results were consistent for VMS severity, bother, and interference. Low-dose estradiol reduced the frequency of symptoms by 0.6 more per day than venlafaxine (P?=?.09). Treatment satisfaction was highest (70.3%) for estradiol (P?<?.001 vs placebo), lowest (38.4%) for placebo, and intermediate (51.1%) for venlafaxine (P?=?.06 vs placebo). Both interventions were well tolerated.Low-dose oral estradiol and venlafaxine are effective treatments for VMS in women during midlife. While the efficacy of low-dose estradiol may be slightly superior to that of venlafaxine, the difference is small and of uncertain clinical relevance.clinicaltrials.gov Identifier: NCT01418209.

Project description:Background:Low-dose methotrexate (LD-MTX) is the most commonly used drug for systemic rheumatic diseases worldwide and is the recommended first-line agent for rheumatoid arthritis. Despite extensive clinical use for more than 30 years, few data on adverse event (AE) rates derive from randomized, placebo-controlled trials, where both causality and magnitude of risk can be inferred. Objective:To investigate AE rates, risk, and risk differences comparing LD-MTX versus placebo. Design:Prespecified secondary analyses of a double-blind, placebo-controlled, randomized trial. (ClinicalTrials.gov: NCT01594333). Setting:North America. Participants:Adults with known cardiovascular disease and diabetes or metabolic syndrome. Intervention:Random allocation to LD-MTX (?20 mg/wk) or placebo. All participants received folic acid, 1 mg/d, 6 days per week. Measurements:Risks for specific AEs of interest, as well as for all AEs, were compared across treatment groups after blinded adjudication. Results:After an active run-in period, 6158 patients were enrolled and 4786 randomly assigned to a group; median follow-up was 23 months and median dosage 15 mg/wk. Among the randomly assigned participants, 81.2% were male, median age was 65.7 years, and median body mass index was 31.5 kg/m2. Of 2391 participants assigned to LD-MTX, 2080 (87.0%) had an AE of interest, compared with 1951 of 2395 (81.5%) assigned to placebo (hazard ratio [HR], 1.17 [95% CI, 1.10 to 1.25]). The relative hazards of gastrointestinal (HR, 1.91 [CI, 1.75 to 2.10]), pulmonary (HR, 1.52 [CI, 1.16 to 1.98]), infectious (HR, 1.15 [CI, 1.01 to 1.30]), and hematologic (HR, 1.15 [CI, 1.07 to 1.23]) AEs were elevated for LD-MTX versus placebo. With the exception of increased risk for skin cancer (HR, 2.05 [CI, 1.28 to 3.28]), the treatment groups did not differ in risk for other cancer or mucocutaneous, neuropsychiatric, or musculoskeletal AEs. Renal AEs were reduced in the LD-MTX group (HR, 0.85 [CI, 0.78 to 0.93]). Limitation:The trial was done in patients without rheumatic disease who tolerated LD-MTX during an active run-in period. Conclusion:Use of LD-MTX was associated with small to moderate elevations in risks for skin cancer and gastrointestinal, infectious, pulmonary, and hematologic AEs, whereas renal AEs were decreased. Primary Funding Source:National Institutes of Health.

Dataset Information

Low-dose hydrocortisone reduces norepinephrine duration in severe burn patients: a randomized clinical trial.

Publications

Low-dose hydrocortisone reduces norepinephrine duration in severe burn patients: a randomized clinical trial.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure